Search Results

You are looking at 351 - 360 of 2,919 items for :

  • Refine by Access: All x
Clear All
Full access

Oncology Research Program

. Four different dose schedules of perifosine with temsirolimus will be tested. Primary Outcome Measures: Maximum tolerated dose (MTD) of combination perifosine and temsirolimus in children with cancer Secondary Outcome Measures: Determine

Full access

Primary Mediastinal B-Cell Lymphoma in Children and Young Adults

Christopher J. Forlenza, Amy Chadburn, and Lisa Giulino-Roth

biology, diagnosis, and treatment of PMBCL in children and young adults and summarizes future directions to advance outcomes in this distinct lymphoma subtype. Biology of PMBCL The morphologic and immunophenotypic appearance of PMBCL in children is

Full access

NCCN Roundtable:Value-Based Decision-Making at the Bedside

Peter B. Bach, Stephen B. Edge, Linda House, Jennifer Malin, James L. Mohler, and Clifford Goodman

, Senior Vice President and Principal, The Lewin Group, Falls Church, Virginia. Peter B. Bach, MD, MAPP, Director, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center, New York, New York. Stephen B. Edge, MD, Cancer Center

Full access

Risk Stratification and Selection of Management Strategy for Localized Prostate Cancer

Presented by: Alice Yu

Novel risk stratification strategies, including tumor multigene molecular testing and multimodal artificial intelligence (MMAI) assays, are emerging as powerful tools to refine treatment decisions and optimize outcomes for patients with localized

Full access

Using the Science of Psychosocial Care to Implement the New American College of Surgeons Commission on Cancer Distress Screening Standard

Lynne I. Wagner, David Spiegel, and Timothy Pearman

standards to promote patient-centered care, an exciting shift driven by research over the past decade showing that patient-centered services improve outcomes. CoC patient-centered standards include the provision of treatment and survivorship plans

Full access

Trends in Incidence and Factors Affecting Survival of Patients With Cholangiocarcinoma in the United States

Shiva Kumar R. Mukkamalla, Hussain M. Naseri, Byung M. Kim, Steven C. Katz, and Vincent A. Armenio

statistics were performed for categorical and ordinal variables using frequencies. Differences among subgroups were evaluated using the chi-square test. The primary outcome was 5-year OS. Cox proportional hazards model was used to perform multivariate

Full access

NCCN Guidelines® Insights: Cervical Cancer, Version 1.2024

Featured Updates to the NCCN Guidelines

Nadeem R. Abu-Rustum, Catheryn M. Yashar, Rebecca Arend, Emma Barber, Kristin Bradley, Rebecca Brooks, Susana M. Campos, Junzo Chino, Hye Sook Chon, Marta Ann Crispens, Shari Damast, Christine M. Fisher, Peter Frederick, David K. Gaffney, Stephanie Gaillard, Robert Giuntoli II, Scott Glaser, Jordan Holmes, Brooke E. Howitt, Jayanthi Lea, Gina Mantia-Smaldone, Andrea Mariani, David Mutch, Christa Nagel, Larissa Nekhlyudov, Mirna Podoll, Kerry Rodabaugh, Ritu Salani, John Schorge, Jean Siedel, Rachel Sisodia, Pamela Soliman, Stefanie Ueda, Renata Urban, Emily Wyse, Nicole R. McMillian, Shaili Aggarwal, and Sara Espinosa

well recognized, the availability of several agents targeting these specific biomarkers has led to improved outcomes in patients. Several new biomarker-based immune-oncologic agents have been added to the guidelines for the management of recurrent

Full access

Adult Acute Lymphocytic Leukemia: Strategies for Selection of Consolidation Therapy

Presented by: Aaron C. Logan

received BFM-like therapy and compared the outcomes of those who received blinatumomab versus those who did not. 10 “Just under 60% of the 488 enrolled patients progressed to randomization due to a substantial drop-off,” said Dr. Logan. “For those

Full access

HSR19-103: Burden of Self-Reported Mental Health Among Women With Cervical Cancer (CC) in the United States

Chizoba Nwankwo and Michael J. Doane

patient-reported outcomes, including symptoms of depression and anxiety, amongst women with and without a diagnosis of CC. Methods: Data were aggregated from the 2016–2018 U.S. National Health and Wellness Surveys, a nationally representative, self

Full access

Localized Renal Cell Cancer: A Testing Ground for New Approaches and Technology

Rodger J. Winn

for radical nephrectomy in one half of patients . Urol Oncol 2004 ; 22 : 36 - 39 . 5 Kercher KW Heniford BT Matthews BD . Laparoscopic versus open nephrectomy in 210 consecutive patients: Outcomes, costs, and changes in practice patterns